SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced ...
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing ...
The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...
Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients ...
Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year.New, potentially bes ...
Explore a potential trade with CytomX (CTMX) stock as Q1’26 clinical data approaches for its EpCAM-targeting therapy. Read ...
After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...
Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting ...
As Tubulis prepares to unveil the first in-human data on its next-generation antibody drug conjugate (ADC) later this month, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback